Fiche publication
Date publication
avril 2026
Journal
Journal of medicinal chemistry
Auteurs
Membres identifiés du Cancéropôle Est :
Dr COLLIN Bertrand
,
Dr BELLAYE Pierre-Simon
Tous les auteurs :
Fabre C, Godard A, Privat M, Moreau M, Dalonneau F, Sickinger A, Maury O, Bellaye PS, Collin B, Busser B, Righini CA, Goze C, Bodio E, Sancey L
Lien Pubmed
Résumé
The study reports the synthesis and biological evaluation of , a novel bimodal imaging probe based on a water-soluble NIR-II aza-BODIPY fluorophore. The platform enables the design of a bimodal imaging probe through conjugation to the anti-epithelial growth factor receptor (EGFR) antibody cetuximab and incorporation of a [In]In-DOTA complex for single-photon emission computed tomography (SPECT) imaging. The resulting probe efficiently targets EGFR-expressing tumors in a murine model of head and neck squamous cell carcinoma (HSNCC). Multimodal imaging combining NIR-I/NIR-II fluorescence and SPECT revealed specific tumor accumulation and a strong spatial correlation between optical and SPECT signals, demonstrating that DOTA grafting does not compromise fluorophore behavior or stability. These results establish as a promising dual-modality contrast agent for peroperative tumor localization and future fluorescence-guided surgery (FGS), enabling complementary deep-tissue and high-resolution imaging.
Référence
J Med Chem. 2026 04 21;:
